MAP2K7 and melanoma: Acquisition of mutations affecting a variety of components of the RTK-RAS-RAF-MEK-ERK pathway, but also parallel pathways including the PI3K-AKT pathway, enable melanoma cells to resist MAPK signaling inhibition.